WARSAW, Ind., Dec. 8, 2011 /PRNewswire/ -- Zimmer Holdings, Inc. (NYSE: ZMH; SIX: ZMH), a global leader in musculoskeletal care, today announced the availability of its CLS® Brevius Hip Stem with Kinectiv® Technology in the United States. This new technology enables surgeons to better match patients’ individual anatomies with modular neck options designed for independent, intraoperative adjustments.
“Following its introduction in Europe earlier this year, we have received excellent clinical feedback on the performance of the new CLS Brevius Stem,” said Jeff McCaulley, President, Zimmer Reconstructive. “Incorporating Kinectiv Technology to this new stem provides unparalleled intraoperative flexibility for our customers to restore their patients’ anatomies.”
The new hip stem is based on the Zimmer CLS Spotorno® Stem, one of the most reliable implants worldwide with more than 25 years of clinical use. Since its introduction in the 1980s, the CLS Spotorno Stem has been used in more than 560,000 total hip arthroplasty procedures around the world. The CLS Spotorno Stem is characterized by excellent primary and rotational stability in uncemented total hip arthroplasty.
Building on this history of clinical success, the new CLS Brevius Hip Stem provides greater intraoperative flexibility with the addition of Kinectiv Technology. Kinectiv Technologyoffers a wide array of head center locations, enabling independent, intraoperative control of leg length, offset and version for a more accurate restoration of the patient’s natural anatomy. The CLS Brevius Stemwith Kinectiv Technologyis shorter than conventional stems, providing greater bone conservation compared with the original CLS Spotorno Stem.
For more information about the advantages of CLS Brevius Stemwith Kinectiv Technology, please visit www.zimmer.com.
About the Company
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related surgical products. Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries. Zimmer’s 2010 sales were approximately $4.2 billion. The Company is supported by the efforts of more than 8,000 employees worldwide.
Zimmer Safe Harbor Statement
This press release contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 based on current expectations, estimates, forecasts and projections about the orthopaedics industry, management’s beliefs and assumptions made by management. Forward-looking statements may be identified by the use of forward-looking terms such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “assumes,” “guides,” “targets,” “forecasts,” and “seeks” or the negative of such terms or other variations on such terms or comparable terminology. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that could cause actual outcomes and results to differ materially. For a list and description of such risks and uncertainties, see our periodic reports filed with the U.S. Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports. Readers of this document are cautioned not to place undue reliance on these forward-looking statements, since, while we believe the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this document.
SOURCE Zimmer Holdings, Inc.
